Minqi Cai
Qian Zheng2†
Bing Bai- 1Department of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College of Jiangsu University, Nanjing, Jiangsu, China
- 2Health Management Center, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China
- 3Center for Precision Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China
- 4Chemistry and Biomedicine Innovation Center, Medical School of Nanjing University, Nanjing, China
Netrin-1 was initially discovered as a neuronal growth cue for axonal guidance, and its functions have later been identified in inflammation, tumorigenesis, neurodegeneration, and other disorders. We have recently found its alterations in the brains with Alzheimer’s disease, which might provide important clues to the mechanisms of some unique pathologies. To provide better understanding of this promising molecule, we here summarize research progresses in genetics, pathology, biochemistry, cell biology and other studies of Netrin-1 about its mechanistic roles and biomarker potentials with an emphasis on clinical neurodegenerative disorders in order to expand understanding of this promising molecular player in human diseases.
1 Introduction
Netrin-1 is a canonical chemotropic cue for axon guidance. The discovery of netrins can be traced back to the 1890s when Dr. Cajal proposed that axons may be guided by diffusible cues that attracted the projections of spinal commissural neuron axons toward the ventral midline of the embryonic spinal cord where these cues were secreted and formed a chemotropic gradient in the neuroepithelium (Moore et al., 2007). Netrin-1, along with Netrin-2, was initially discovered and purified in embryonic chicken brain homogenate. Subsequently, other netrin family proteins have been identified or implicated in Drosophila, mice, and humans (Moore et al., 2007). Now netrins are found to not only function in axon pathfinding but also play key roles in other diverse cellular processes including, cell migration, adhesion, differentiation, and survival, with involvements in neurodegeneration (Jasmin et al., 2021), inflammation (Xia et al., 2022), cancer and other clinical diseases (Lengrand et al., 2023). Netrin-1 has been studied in Parkinson’s Disease (PD), Alzheimer’s disease (AD) and other types of neurological disorders, and we have found new evidence of Netrin-1 involved in AD pathogenesis (Bai et al., 2020). Here we provide an overview of Netrin-1 to highlight its mechanistic roles and biomarker potentials in these neurological disorders.
The netrin family proteins belong to the superfamily of laminin-like proteins and contains Netrin-1, Netrin-3, Netrin-4, Netrin-G1, and Netrin-G2 in mammals. Netrin-3 is more similar to Netrin-1 share more about 50% amino acid identity while Netrin-4 and Netrin-5 are more distinct (Rajasekharan and Kennedy, 2009). Netrin-1, Netrin-3, Netrin-4, and Netrin-5 are secreted proteins and are involved in axonal migration and neuronal growth during development of the central nervous system. In contrast, Netrin-G1 and Netrin-G2 are largely different from Netrin-1 in protein sequence and they are GPI membrane linked (Sun et al., 2011). These two proteins have not been implicated in axon guidance or neuronal growth, but have a well described role in regulating synapse formation (Rajasekharan and Kennedy, 2009; Matsukawa et al., 2014). For these distinct properties, Netrin-G1 and Netrin-G2 make up a distinct subfamily (Sun et al., 2011).
Netrin-1 is widely expressed in normal adult tissues with highest levels in the gastrointestinal tract and the muscle tissues according to the human protein atlas database1. In the human adult brain, it is present almost universally in all regions with a relatively high level in the midbrain. In the prefrontal cortex, it is slightly more abundant in posterior cingulate, piriform and retrosplenial cortices. However, the human tissue proteome analysis demonstrates its protein expression is selectively high at the gallbladder and the urinary bladder (Kim et al., 2014). This analysis also shows the Netrin-1 protein is highly expressed in NK cells in the peripheral blood. Other studies report its expression in macrophages, endothelium and epithelium cells (van Gils et al., 2012, 2013; Ramkhelawon et al., 2014; Bruikman et al., 2020a).
As recorded in the UniProt database2, Human Netrin-1 is a secreted protein and consists 604 amino acids with extensive disulfide bonds. The Netrin-1 protein contains a highly conserved a N-terminal laminin domain (typically referred to as domain VI), three cysteine-rich EGF-like repeats (referred to as domain V) and a positively charged netrin-like (NTR) module at the C-terminus with a motif of the cell attachment site (Rajasekharan and Kennedy, 2009).
Netrin-1 regulates neuronal axon guidance in human mainly through the DCC (deleted in colorectal cancer) and UNC-5 receptors (uncoordinated-5 homolog family members, UNC5A, UNC5B, UNC5C and UNC5D), and other possible receptors that include neogenin (Moore et al., 2007), DSCAM (Down syndrome cell adhesion molecule) (Ly et al., 2008; Liu et al., 2009), Adora2b (adenosine receptor A2b)(Corset et al., 2000), CD146 and integrin subunits (Stanco et al., 2009; Lemons et al., 2013; Tu et al., 2015; Li et al., 2023). The UNC5C proteins are mainly involved in axonal repulsion while the DCC receptors regulate axonal attraction through their bindings with Netrin-1 at different affinities (Boyer and Gupton, 2018). Besides, DCC and the UNC5 proteins also regulate apoptosis, either promoting it in the absence of Netrin-1 or inhibiting it in the presence of Netrin-1, and thus they are called “dependence receptors” (Llambi et al., 2001; Arakawa, 2004; Tang et al., 2008). However, these effects are also contradicted by findings in which Ntn1 null mice fails to fully recapitulate the phenotypes of Unc5−/− mice and Ntn1−/− mouse embryos exhibit increased expression of DCC and neogenin with no increased apoptosis (Bin et al., 2015; Yung et al., 2015).
The reports about DSCAM and Adora2b as netrin receptors are controversial. Subsequent to the initial description, compelling evidence has shown DSCAM to be irrelevant for netrin dependent commissural axon guidance in the embryonic spinal cord and instead appears to function as a homophilic adhesion protein that promotes axon fasciculation independent of netrins (Palmesino et al., 2012; Cohen et al., 2017). Although Netrin-1 is reported to interact with Adora2b to mediate axon outgrow and cAMP production, there is also contradictory evidence showing that Netrin-1 does not increase the concentration of intracellular cAMP in neurons (Moore and Kennedy, 2006; Moore et al., 2008).
Netrin-1 regulates axon guidance through different receptors it binds (e.g., DCC/DCC for chemoattraction, UNC5/DCC for long-range repulsion and UNC5/DSCAM for short-range repulsion), intracellular secondary messengers (e.g., cAMP, Ca++, cGMP), its own local level (low level of Netrin-1 activates DCC/DCC homodimerization to exert chemoattraction and high level of Netrin-1 induces UNC5/DCC heterodimerization for repulsion), and existence of other modulators in the extracellular environment (e.g., draxin, glycosaminoglycans, the binders of Netrin-1) (Sun et al., 2011; Boyer and Gupton, 2018). In canonical chemoattraction, Netrin-1 binds to DCC receptors and thus induces their homodimerization. This activates constitutively bound NCK1 (non-catalytic region of tyrosine kinase adaptor protein 1) and FAK (focal adhesion kinase) which starts recruitment of numerous intracellular signaling components to activate Src family kinases and Rho GTPases, release Ca++ stores, stimulate protein translation, leading to rearrangement of the actin cytoskeleton eventually (Sun et al., 2011).
Although Netrin-1 and other members in the family are extensively studied as essential chemotropic cues for migrating cells and axons during neural development, it is now evident that the netrin proteins and their receptors are also involved in other biological processes both throughout development and in adulthood, including adult stem cell migration, tumorigenesis, inflammation (Arakawa, 2004; Petit et al., 2007; Sun et al., 2011; Zhang et al., 2018; Xia et al., 2022; Cassier et al., 2023; Lengrand et al., 2023).
We recently find that the Netrin-1 expression is significantly increased in the brain tissue of patients with Alzheimer’s disease (AD), and highly correlated with Aβ in their levels. Netrin-1 colocalizes with Aβ within the plaques in both human and mouse brain tissue and starts expressing inside neurons with Aβ at the early stage. Importantly, a receptor of Netrin-1, UNC5C, has a mutation in a familial AD (Wetzel-Smith et al., 2014). These suggest that Netrin-1 is an important player in AD pathogenesis and might provide plausible explanations for some intriguing common pathologies. In consideration that Netrin-1 is also a critical factor in Parkinson’s disease (PD) and that mutation of Netrin-1 can cause neurological disorders directly, we here summarize the genetics, pathology, biochemistry, cell biology and other evidence in research progress about Netrin-1 to provide better understanding of Netrin-1 as a promising molecular in molecular mechanism and biomarker potential in these neurodegenerative diseases.
2 Genetic diseases of Netrin-1
The clinical significance of a molecule is best implicated by its related genetic variation and the resulting diseases. Mutations of the gene (NTN1) that encodes for Netrin-1 is associated with congenital mirror movements. This is an autosomal dominant disorder characterized by involuntary movements on one side of the body that accompany and mirror intentional movements on the other side (Online Mendelian Inheritance in Man, OMIM, # 618264). Three mutations (I518del, C601R, C601S) have been found on NTN1 that cause this type of neurological abnormality (Meneret et al., 2017). These patients have more ipsilateral corticospinal tract projections and in cultured cells proteins bearing these mutations fail to be secreted (Meneret et al., 2017). It is notable that causative gene mutations in congenital mirror movements also include DCC and RAD51, in which DCC is the receptor of Netrin-1 and RAD51 negatively regulates Netrin-1 signaling (Meneret et al., 2014; Franz et al., 2015; Glendining et al., 2017). This strengthens the potential involvement of the Netrin-1 regulatory pathway in this disease.
According to the human gene mutation database (Stenson et al., 2020), other genetic variations with NTN1 are also indicated in autism spectrum disorder (A449D) (Iossifov et al., 2014), adult-onset hearing loss (T375P) (Lewis et al., 2018), intellectual disability (V429M) or hypogonadotropic hypogonadism (R362C, T525R) respectively (Bouilly et al., 2018; Hu et al., 2019), although NTN1 are not the primary mutated gene in these diseases and further validations are needed.
3 Involvement of Netrin-1 in Alzheimer’s disease
Alzheimer’s disease (AD) is an aging related irreversibly progressive neurodegenerative disorder that represents about 65% of dementia cases in people over 65 years old (Tahami Monfared et al., 2022). Although some drugs such as Lecanemab have been developed and approved by FDA in America, more evidence is needed to establish their effectiveness and safeness (Burke et al., 2023; Couzin-Frankel, 2023; van Dyck et al., 2023).
AD is hallmarked by extracellular amyloid plaques and intracellular neurofibrillary tangles (NFTs) in brain cortical tissues with other frequent concomitant but not unique pathologies like amyloid angiopathy, brain atrophy, synaptic loss, white matter rarefaction, granulovacuolar degeneration, neuronal death, TDP-43 proteinopathy, neuroinflammation (Masters et al., 2015). Aβ amyloid pathology initially occurs as a few patches in poorly myelinated areas in basal parts of the neocortex, and then gradually increases and eventually spread to the entire cortex and subjacent portions of the underlying white matter (Braak and Braak, 1996). In contrast, the NFTs start early in the transentorhinal region of the medial temporal lobe and this can happen even at young ages. Later these tangles progress more severely into both entorhinal and transentorhinal regions until its culmination in neocortical and primary sensory areas eventually (Braak and Braak, 1996). It takes about 50 years from the first appearance of transentorhinal NFTs to the end stage of AD (Ohm et al., 1995), which is partially consistent with the pattern of memory and cognitive decline. Therefore, developments of Aβ plaques and NFTs do not follow the same temporal or anatomic pattern during aging in the brain. It is also notable that NFTs in the medial temporal lobe are universally present in subjects older than 70 years while Aβ plaques are found only in a significant proportion of the older population but are not universal (Nelson et al., 2012). Besides, the Aβ plaque burden in the brain is not correlated with the dementia severity while the number of NFTs are highly correlated with the number of dying neurons as well as the dementia scores (Nelson et al., 2012).
The cores of these aggregated protein deposits are Aβ peptides and hyperphosphorylated protein Tau (MAPT, microtubule-associated protein Tau) respectively (Duyckaerts et al., 2009). The Aβ peptides (40, 42, 43 and other number of amino acids long) are generated from the protein APP through sequential cleavage by the β-secretase (such as BACE1) and the γ-secretase that includes PSEN and other components probably in late endosomes and trans-Golgi apparatuses (Greenfield et al., 1999). Aβ42 is more prone to aggregation and soluble forms of these Aβ species (dimers, tetramers, oligomers) are considered more neurotoxic (Haass and Selkoe, 2007). The protein Tau has 44 phosphorylated sites and 28 of which are elevated in AD, which involves nearly 20 kinases including GSK3β (Glycogen synthase kinase-3 β), CDK5 (cyclin-dependent protein kinase-5), MAPK (mitogen-activated protein kinases), etc. (Martin et al., 2013; Tan et al., 2015; Bai et al., 2020).
So far, all three familial AD genes (APP, PSEN1, PSEN2) are directly involved in Aβ generation (Yu et al., 2021). Mutations that cause overproduction of Aβ promotes the development of AD while those that inhibit Aβ production protects people from AD (Jonsson et al., 2012). In combination with evidence from pathology, biochemistry, cell biology and animal work, it is generally posited in the field that Aβ is the initiator of this devastating disease and Tau mediates its full development (Bloom, 2014).
Besides Aβ and Tau, inflammation is another important player in AD pathogenesis (Heppner et al., 2015). Among the list of AD genetics, half of the risk factors are related to inflammation processes (Yu et al., 2021). Inflammation is considered as a central mechanism in AD (Kinney et al., 2018). First, in AD brain cortices, complement system protein components C1q, C3b, C3c, C3d, and C4 are found to localize within the amyloid plaques (Eikelenboom and Stam, 1982), and fibrillar Aβ peptides and neurofibrillary tangles can activate directly the complements in vitro (Tenner, 2020). AD risk genes such as TREM2, CR1, CD33, CLU are close regulators of the complement system. Besides the complements, microglia are another very important inflammatory factor in AD. Activated microglia almost universally colocalize with Aβ plaques in the AD brain tissue and they correlate with both neuropathological stages of disease severity and clinical severities of dementia (Leng and Edison, 2021). The progression and expansion of activated microglia closely parallel that of neuritic plaques in AD brains across different and regions from the hippocampus to the temporal lobe until the frontal and occipital lobes where they coexist in same cortical layers (Mrak, 2012). In addition, increased levels of pro-inflammatory mediators, such as tumor necrosis factor (TNF), IL-1β, IL-6, prostaglandins, reactive oxygen species and reactive nitrogen species, are found in brain tissues, consistent with the activation of microglia (Mrak and Griffin, 2005; Gyengesi and Munch, 2020). In fact, epidemiological and observational studies have reported that long-term treatments of inflammation diseases (such as rheumatoid arthritis) with nonsteroidal anti-inflammatory drug (NSAID) showed about 50% reduction in the risk for developing AD (Kinney et al., 2018). Inflammation in AD appears to exert a dual function, probably be neuroprotective at the early stage while lose control and become detrimental (Leng and Edison, 2021).
The involvement of Netrins in AD pathogenesis is highlighted by discovery of mutations in its receptor UNC5C in familial AD patients. A rare mutation T835M in the coding region of UNC5C segregate with AD in two families in an autosomal dominant pattern and it was associated with disease across four large case–control cohorts with the odds ratio of 2.15 (Wetzel-Smith et al., 2014). T835M is a conserved site in the hinge region of UNC5C and this mutation enhances cell death and potentiates the neurotoxicity of Aβ in vitro (Wetzel-Smith et al., 2014). Besides, UNC5C cleavage by δ-secretase at amino acids N467 and N547 enhances subsequent caspase-3 activation to potentiate its proapoptotic activity, facilitating neurodegeneration in AD (Chen et al., 2021). In combination with the report that UNC5H acts as a dependence receptor to induce apoptosis when the netrin ligands are absent (Llambi et al., 2001), UNC5C in the presence of Netrin-1 in AD might be considered protective. It is also notable that Netrin-5 is among the 38 genomic risk loci identified from 90,338 (46,613 proxy) cases and 1,036,225 (318,246 proxy) controls, indicating a strong association with AD as an outstanding disease mechanistic clue.
Indeed, Netrin-1 interacts with APP and modulates Aβ production and function to exert protective effects on cells and neurons. Netrin-1 is not only coimmunoprecipitated with APP from cultured cells, recruited to the plasma membrane of APP-expressing cells, but also colocalizes with APP in the growth cones of cortical neurons (Lourenco et al., 2009). This binding is mediated by involvement of several domains of Netrin-1 and the Aβ region of APP. Structural analysis reveals that Netrin-1 binds to the amino acids 4–16 of Aβ, repeatedly positioning the hydrophobic F352 side chain, toward grove 4–8 amino acids of Aβ and this is favored by the hydrophobic F4 of Aβ (Borel et al., 2017). The binding between Netrin-1 and APP leads to increased translocation of the fragment of APP intracellular domain (AICD) from cytoplasm to the nucleus, thus promoting AICD-dependent gene transcription (Lourenco et al., 2009). Mutually, through this binding, APP also regulates Netrin-1 in commissural axon navigation through the DCC receptor complex. Inactivation of APP in mice is associated with reduced commissural axon outgrowth (Rama et al., 2012).
Binding with Netrin-1 also modulates Aβ production and aggregation. It is well known that under the physiological condition, APP undergoes nontoxic cleavage by the α-secretase ADAM10 (a disintegrin and metalloprotease), while in the pathological situation of AD, β-secretase mediated cleavage to generate Aβ peptides is increased. It is found that Aβ peptides are substrates of ADAM10 and inhibit this protease, shifting the α-cleavage to β-cleavage, exerting a self-amplification effect (Spilman et al., 2016). However, this effect is inhibited by Netrin-1 in cultured cells and neurons, and Netrin-1 expression suppressed both Aβ40 and Aβ42 levels in the transgenic mice that overexpress Aβ40, probably due to binding of Netrin-1 in the Aβ region of APP, prevent it from β-cleavage to generate Aβ (Spilman et al., 2016). This provides a potential therapeutic approach for control of Aβ generation in in AD brains.
In mice, Netrin-1 restores memory performance impaired by exogenously administered Aβ. Repeated intracerebroventricular injection of Netrin-1 rescued long-term potentiation reduction and memory impairment in the maintenance phase in all cognitive behavioral tasks (Shabani et al., 2017). This might be supported by the fact that selective homozygous deletion of Netrin-1 or its receptor DCC from glutamatergic neurons in the forebrain, including hippocampal CA1 pyramidal neurons, results in significant impairment of memory consolidation (Glasgow et al., 2021), suggesting the critical role of Netrin-1 in maintenance of synaptic plasticity and thus memory in turn.
The neuronal protection from Netrin-1 on the Aβ insults might be related to its suppression on inflammation, oxidation and apoptosis. Treatment of SH-SY5Y cells exposed to Aβ42 peptides with Netrin-1 increased cell viability and partially restored the expression levels of the inflammatory factors TNFα and NF-κB and the oxidation marker nuclear factor erythroid 2–like 2 (Nrf2) (Zamani et al., 2020). The Netrin-1 treatment is also able to reduce caspase-3/7activities induced by intrahippocampal injection of Aβ42 in mice (Zamani et al., 2019). Specific mechanisms of these neuronal protective effects of Netrin-1 still remain to be clarified.
In our ultradeep mass spectrometry based quantitative proteomics analysis, we have found Netrin-1 is extremely correlated with Aβ in their levels not only in brains of human AD patients but also in those of mice that overexpress Aβ (Bai et al., 2020). Besides, Netrin-1 colocalizes with Aβ plaques in both AD human and mouse brain cortices, and it can directly bind Aβ peptides in vitro (Bai et al., 2020). Further experiments in our preliminary studies show that Netrin-1 starts to occur in neurons when Aβ becomes observable in 5xFAD mice at ages of 1, 2 and 3 months. From these lines of evidence, we might speculate that Aβ can possibly induce protein expression of Netrin-1 which in turn promotes Aβ aggregation through direct binding, forming a vicious cycle.
In AD, there is a prominent pathology in brain cortex that amyloid plaques are commonly surrounded by microglia and this might be related to Netrin-1. It is reported that Netrin-1 can arrest macrophages and inactivate their egress from atherosclerotic plaques (van Gils et al., 2012). Netrin-1 does so by binding to its receptor UNC5b to inhibit activation of the actin-remodeling GTPase Rac1 and actin polymerization, making macrophages anergic (van Gils et al., 2012). The same phenomenon can be seen in obesity where Netrin-1 induced by the saturated fatty acid palmitate acts through its UNC5b to retain macrophages in the adipose tissues (Ramkhelawon et al., 2014). Therefore, as the type of the macrophages in the central nervous system, microglia might also similarly be sequestered around the plaques where Netrin-1 is enriched. If this is finally turned out to be true, Netrin-1, again, should be a promising target for early therapeutic intervention of inflammation control in AD.
It is important to mention that the high correlation of Netrin-1 with Aβ is also seen in the Aβ-overexpressing 5xFAD mice, suggesting that Aβ can induce elevated protein level of Netrin-1. Because the RNA-seq data of these mice do not show altered mRNA level of Netrin-1 (Chen P. C. et al., 2022), the regulation is highly likely achieved at the protein level and this can be explained by two possible mechanisms, sequestering Netrin-1 either by direct binding or through binding of proteins that regulate Netrin-1 traffic in the secretory pathway (Kanekiyo et al., 2013; Sollvander et al., 2016; Marshall et al., 2020). If these are evidenced, the elevated Netrin-1 and other proteins (such as Midkine, Netrin-3, CTHRC, etc.) not only cause gain-of-function-like problems where they are accumulated, but also more importantly cause loss-of-function-like issues resulting from insufficient cellular secretion due to sequestration.
4 Involvement of Netrin-1 in Parkinson’s disease
Parkinson’s disease (PD) is the second major neurodegenerative disorder that mainly affects movement in senior population, manifesting rigidity, slowness, and tremor and other non-motor symptoms (Emamzadeh and Surguchov, 2018). It is caused by neuronal loss in the substantia nigra, resulting in insufficient synthesis of dopamine to maintain normal neuronal activities for movement control. In the brain, PD is hallmarked by intracellular inclusions of aggregated protein α-synuclein known as Lewy Bodies (Poewe et al., 2017). The underlying molecular mechanisms of pathogenesis include α-synuclein proteostasis, mitochondrial function, oxidative stress, calcium homeostasis, axonal transport, neuroinflammation and other potential biological processes and cellular signaling (Poewe et al., 2017).
Netrin-1 and its receptor DCC are highly expressed in adult brains in dopaminergic neurons of the substantia nigra pars compacta (SNpc) which is selectively affected in PD (Osborne et al., 2005). Netrin-1 can also be produced in the forebrain and transferred through axons to the midbrain, to direct migration of GABAergic neurons into the ventral SN during development, confining dopaminergic (DA) neurons within the dorsal SN (Brignani et al., 2020). Netrin-1 acts on DA neurons at both ventral tegmental area (VTA) and SN, but these two populations of DA axons respond differentially: VTA axons prefer higher concentrations while SN axons require lower concentrations, so that topographic distribution of specific neuron types can be maintained (Li et al., 2014).
According to recent data, Netrin-1 may be associated with PD pathogenesis. During aging, Netrin-1 is substantially reduced in the brain and this is more significant in PD patient brains although this is possibly due to loss of dopaminergic neurons which are the major source of Netrin-1 (Ahn et al., 2020b). In PD mouse models, imbalance of NTN-1 and DCC is found to be a common feature in nigral DA neurons in which the well-established chemical PD inducer MPP+ (1-Methyl-4-phenyl pyridinium iodide) inhibits the expression of Netrin-1 but increases DCC expression in both concentration- and time-dependent manners (Hua et al., 2023). Normally, only Netrin-1 is significantly expressed in the substantia nigra of healthy adult brains while α-synuclein is basally present and their protein levels are inversely correlated. It is actually found that Netrin-1 and α-synuclein can directly interact with each other and Netrin-1 blocks α-synuclein aggregation in vitro; besides, Netrin-1 deprivation initiates α-synuclein aggregation in cultured primary DA neurons (Kang et al., 2023). Therefore, loss of Netrin-1 enhances α-synuclein aggregation and possibly contributes to PD pathogenesis. In vivo, conditional knockout of Netrin-1 specifically in the adult mouse induces DCC cleavage and a significant loss of dopamine neurons, leading to impaired motor function in these mice (Jasmin et al., 2021).
Chronic constipation is a frequent symptom that occurs even before the onset of PD and propagation of the aggregated α-Synuclein-containing Lewy bodies from the gut into the brain has been proposed as a key mechanism in PD etiopathogenesis (Braak et al., 2006). PD mice demonstrate increased intestinal permeability to proinflammatory bacterial products (Kelly et al., 2014), imposing the oxidative stress on the enteric neurons (Forsyth et al., 2011). Research has shown an inverse correlation of Netrin-1 and BDNF (brain-derived neurotrophic factor) with inflammatory cytokines-activated transcription factor CCAAT/enhancer binding protein β (C/EBPβ) in PD patient brains and colons resulting from binding of C/EBPβ to the promoters of Netrin-1 and BDNF genes to inhibit their mRNA expression (Ahn et al., 2020a, 2021).
There are two possible mechanistic pathways that have been studied in the death of DA neurons caused by Netrin-1 insufficiency: one is the mammalian Ste20-like kinases 1 (MST1) and the other is the delta-secretase (asparagine endopeptidase, AEP). The MST1/2 is involved in the Hippo pathway that is critical in controlling tissue growth, cell proliferation, differentiation, and migration in developing organs. Netrin1 reduction activates MST1 which in turn selectively binds and induces phosphorylatin of UNC5B on T428 to generate its apoptotic fragment via active caspase-3 in dopaminergic neurons in the SN. Netrin1 deprivation also causes the downregulation of YAP, a protein involved in ROS scavenge. Both pathways lead to dopaminergic neuronal death. Besides, deficiency of Netrin-1 activates of delta-secretase (asparagine endopeptidase, AEP) which then cleaves both α-Synuclein at N103 and the UNC5C receptor in an age-dependent manner in mice, resulting in accelerated DA neuronal loss and PD phenotypes and pathologies, which can be rescued by AEP deletion. Notably, AEP is highly active in the SNpc regions in human brains with PD where the DA neurons are mainly located and Netrin-1 is highly expressed (Wang et al., 2018; Ahn et al., 2021). However, these are challenged by findings as mentioned earlier in which Ntn1 is unlikely the dominant ligand for Unc5 family and Ntn1−/− mouse embryos exhibit increased expression of DCC and neogenin but no increased apoptosis (Bin et al., 2015; Yung et al., 2015). Besides, deletion of DCC, which is proposed to be pro-apoptotic by the dependence model, is instead required for dopaminergic neuronal survival during aging (Lo et al., 2022), suggesting the impact of Netrin-1 on cell survival is more complex than the mechanisms proposed by the dependence model.
Overall, Netrin-1 is critical to maintain healthy DA neurons in SN and its deficiency is probably one of the key mechanisms in PD etiology.
5 Netrin-1 in psychiatric disorders
Many psychiatric disorders are related to the mesocorticolimbic dopamine system where dopamine cells project from the upper brainstem to the dorsal striatum and multiple cortical and subcortical limbic regions including the ventral striatum nucleus accumbens, olfactory tubercle, septum, hippocampus, amygdala, and cortical regions, particularly the prefrontal cortex, cingulate, and the perirhinal cortex (Vosberg et al., 2020). Genetic variations of Netrin-1/DCC have been shown to associate significantly with depression, schizophrenia, and substance use (Flores, 2011; Hoops and Flores, 2017). This is further evidenced by two other Netrin family members: Netrin-G1 and Netrin-G2 which have shown significant associations in schizophrenia (Aoki-Suzuki et al., 2005). Besides, according to the largest genome-wide meta-analysis of psychiatric disorders conducted so far (~725,000 cases-controls, across eight psychiatric disorders), the intronic DCC SNP rs8084351 shows the most significant and pleiotropic effect (Cross-Disorder Group of the Psychiatric Genomics Consortium, 2019; Torres-Berrio et al., 2020). In addition, results from human postmortem examinations, animal work and GWAS studies suggest that the relevance of the Netrin-1/DCC pathway in the etiology of major depressive disorder due to its abnormal spatiotemporal organization of circuits involved in cognition and emotion (Torres-Berrio et al., 2020). In mice, Dcc haploinsuffificiency results in impaired dopamine transmission and dopamine-related behaviors in adulthood (Flores, 2011; Hoops and Flores, 2017).
6 Netrin-1 in other clinical diseases
The Netrin-1 has already been extensively studied in other diseases such as inflammation, angiogenesis, diabetes, atherosclerosis and tumorigenesis (Xia et al., 2022). In the acute inflammation of ischemia–reperfusion (I/R) injury, the protein level of Netrin-1 is reduced in the affected tissues such as kidney, liver, lung and myocardium (Zhang and Cai, 2010; Ranganathan et al., 2013; Schlegel et al., 2016). Mice heterozygous for Netrin-1 deficiency (Ntn1+/−) undergo more activated inflammation and manifest severer hepatic I/R injury (Schlegel et al., 2016). Treatment with Netrin-1 or its peptides in cultured cells or mice largely alleviates inflammation (Zhang and Cai, 2010; Bouhidel et al., 2014; Cui, 2015; Boneschansker et al., 2016; Liu et al., 2019; Chen et al., 2020b). Netrin-1 exerts these protections by inhibiting production of cytokines (such as IL-2, IL-4, IL-6, IL-13, IL-17, interferon-γ, etc.) and suppressing expression of cyclooxygenase-2 and prostaglandin E2 in T regulatory cells, polymorphonuclear neutrophils and macrophage (Xia et al., 2022), and thus to regulate activation, filtration and polarization of these major inflammatory cells. Specific signaling pathway for these effects involve Netrin-1 and its receptors. For examples, in cardiac I/R, the perfused Netrin-1 binds to its receptor DCC and thus activates the ERK1/2/eNOS pathway to maintain DCC expression via a feed-forward loop and promote generation of nitric oxide (NO·) to protect heart tissues from infarct apoptosis (Zhang and Cai, 2010).
In angiogenesis, Netrin-1 exerts a promoting or inhibiting effect depending on the receptors it binds to or its protein concentration. Upon binding to DCC, Netrin-1 activates the downstream ERK1/2 signaling to phosphorylate eNOS for increase production of endothelial NO, forming a feed-forward signaling cascade to promote angiogenesis (Nguyen and Cai, 2006). Netrin-1 also binds to CD146 or an unknown receptor to enhance endothelial cell growth and migration possibly through other mechanisms (Park et al., 2004; Tu et al., 2015). However, when bound to the receptor UNC5B, Netrin-1 exerts repulsive effects in angiogenesis including endothelial filopodial extension, vessel branching and abnormal navigation (Lu et al., 2004). The bidirectional effects of Netrin-1 in angiogenesis are also concentration-dependent: at low levels, Netrin-1 induces endothelial proliferation, migration and tube formation while at higher doses these effects are inhibited (Xia et al., 2022).
Netrin-1 is also an important molecular player in atherosclerosis, exerting beneficial or disastrous effects depending on its cellular source (Xia et al., 2022). Netrin-1 secreted by endothelial cells is protective as it inhibits chemotaxis of leukocytes and migration of monocytes to atherosclerotic plaques. In contrast, macrophage-derived Netrin-1 is proatherogenic in that it retains macrophage numbers in the plaques (Fiorelli et al., 2021). Besides, a mutation (R590L) within NTN1 is found in a family with premature atherosclerosis, strongly suggest the causative role of Netrin-1 in this common disease (Bruikman et al., 2020b).
In diabetes mellitus and its complications, Netrin-1 is highly expressed in obese adipose tissue of humans and mice, causing retention of macrophages for activated inflammation (Ramkhelawon et al., 2014). It is also significantly altered in the peripheral circulation system (Ay et al., 2016; Liu et al., 2016; Yim et al., 2018). It regulates pancreatic epithelial cell migration and tissue regeneration as well as β-cell apoptosis (De Breuck et al., 2003; Yang et al., 2011). Mice with partial Netrin-1 deficiency demonstrate severer kidney injury in with diabetic nephropathy which can be restored by treatment with recombinant Netrin-1 (Tak et al., 2013). In mice with high-fat diet/streptozotocin-induced diabetes, Netrin-1 treatment increases insulin release from β-cells, promotes islet vascularization, reduces islet macrophage infiltration, and alleviates inflammation (Gao et al., 2016).
The study of Netrin-1 is heated in the cancer field. Netrin-1 is often highly expressed in cancer tissues and involved in tumorigenesis as an oncogene (Arakawa, 2004; Mehlen et al., 2011; Sung et al., 2019). Normally it is expressed mainly during embryonic development, but probably due to the function of anti-apoptosis through its death receptors, Netrin-1 has been found to be highly expressed in tissues of many tumors, including inflammation-associated colorectal cancer (Paradisi et al., 2008, 2009), metastatic breast cancer (Fitamant et al., 2008), endometrial cancer (Cassier et al., 2023), lung cancer (Delloye-Bourgeois et al., 2009a), neuroblastoma (Delloye-Bourgeois et al., 2009b), lymphoma and melanoma (Broutier et al., 2016; Boussouar et al., 2020). According to the globally largest and most comprehensive cancer mutation database (Catalogue of Somatic Mutations in Cancer, COSMIC), point mutations, copy number variation, high expression or methylation of NTN1 is found in almost 30 types of cancers. In animal models, downregulation of Netrin-1 or its receptors promotes cancer cell death and inhibits tumor growth (Broutier et al., 2016; Sung et al., 2019; Boussouar et al., 2020). Based on the causative role of Netrin-1 in cancer pathogenesis and extensive studies showing its efficiency as a therapeutic target, a monoclonal antibody (NP137) that targets Netrin-1 to disrupt its interaction with the UNC5B receptor has been developed and is currently receiving clinical phase 1 trial (NCT02977195) to evaluate safety and efficacy (Grandin et al., 2016; Cassier et al., 2023). The current studies about Netrin-1 in the cancer field is moving rapid and more achievements can be expected in the near future.
7 Biomarker potentials of Netrin-1
Netrin-1 is a secreted protein and can thus be released from the affected tissue regions into body fluid, especially serum, becoming potential biomarkers. In AD, the serum Netrin-1 protein levels are lowered in AD and MCI (mild cognitive impairment) patients and correlated with reduction in dementia scores (Ju et al., 2021). Interestingly, a bilateral intracerebroventricular injection of Aβ42 in rats has not only induced spatial learning and memory deficits and increased neuronal apoptosis, but also reduced Netrin-1 protein levels in both serum and cerebrospinal fluid of these rats with a significant correlation with cognitive deficits (Sun et al., 2019). Besides AD, the serum Netrin-1 is also found to decrease in clinical patients with spinal cord injury and can be an independent risk factor for cognitive impairment in these patients (Meng et al., 2022).
In PD, as the substantia nigra where Netrin-1 is highly expressed is the most affected area in this disease, reduced Netrin-1 protein expression is found in these affected regions of brain tissues from PD patients (Jasmin et al., 2021). Intriguingly, the reduced Netrin-1 level is not only found in PD brain tissues, but also found in the gut where Lewy body-like aggregation first appears in the enteric neurons even before its occurrence in the brain (Ahn et al., 2021). Loss of these neurons that are the major sources of Netrin-1 in these areas might lead to reduced Netrin-1 in the peripheral system. A recent study reveals a significant decrease in plasma Netrin-1 levels with a positive correlation with UPDRS (Unified Parkinson’s Disease Rating Scale) scores in PD patients (Hua et al., 2023), strongly supporting its biomarker potential in this second most common neurodegenerative disease.
Besides the aging-related neurodegenerative disorders, the reduced serum netrin-1 level is also found in ischemic stroke and its complications (Guo et al., 2020; Chen Z. et al., 2022), post-stroke depression (Chen et al., 2020a), and delayed neurological sequelae in unintentional carbon monoxide poisoning (Kokulu et al., 2020); and increased serum Netrin-1 predicts better prognosis of ischemic stroke (Guo et al., 2019; Zang et al., 2021). In fact, altered Netrin-1 levels in serum, urine or types of body fluids are associated with a large number of other clinical diseases, including cancer (Kefeli et al., 2017), atherosclerosis (Munoz et al., 2017; Bruikman et al., 2020a), obesity and diabetes (Yim et al., 2018; Elkholy et al., 2021; Nedeva et al., 2022), kidney Injury (Reeves et al., 2008; Ramesh et al., 2010), brain damage and hemorrhage (Chen et al., 2019; Lou et al., 2020; Xie et al., 2021), periodontitis (Gunpinar et al., 2020; Abdulfattah et al., 2022), acute coronary syndrome (Leocadio et al., 2020), sclerosis (Mulero et al., 2017), preeclampsia (Cekmez et al., 2017; Berenji et al., 2022; Sert, 2022; Kaya et al., 2023).
In cancer, the expression of Netrin-1 is largely altered in lesioned tissues, but its level in serum has not been extensively studied. Increased serum Netrin-1 is found in gastric and lung cancers and it is reduced after chemotherapy, but the levels do not show correlations with the patient survivals (Kefeli et al., 2012; Yildirim et al., 2016). In a large scale of clinical blood samples from cancer patients, plasma Netrin-1 levels are significantly higher in breast, renal, prostate, liver, meningioma, pituitary adenoma, and glioblastoma cancers than it in controls (Ramesh et al., 2011). Recent studies report serum netrin-1 a novel biomarker in colorectal cancer and lung cancer (Li et al., 2020; Zhao et al., 2022).
Although the Netrin-1 level in the peripheral system is changed widely in a large number of diseases, it might bear the potential as a biomarker in diseases of the similar type (such as cancer) or sharing a similar mechanism (such as inflammation).
8 Conclusion
Here we have reviewed Netrin-1 by its genetics, pathology, biochemistry and other biological evidence about its mechanistic involvement and biomarker potential in neurodegenerative, inflammatory, cancerous and other diseases. Mutation of the Netrin-1 gene can cause neurological and other diseases directly, implicating it is not indispensable importance in maintaining normal physiological function. Netrin-1 is highly likely protective in AD, but is also possibly responsible for microglia attraction in the brain tissue. Netrin-1 is critical to dopaminergic neurons in substantia nigra of the brain and its deficiency is critical in both PD pathogenesis and development of psychiatric disorders. It is largely protective in inflammation and the related diseases, bidirectionally effective in atherosclerosis, and generally deleterious as an oncogene in cancer. Besides, Netrin-1 might also be a potential biomarker for these clinical diseases. Here we summarize all these in the Table 1 for better understanding of this promising molecule. Overall, Netrin-1 is a promising protein to be studied across a variety of disease spectra for the discovery of novel molecular mechanisms, potential biomarkers, and therapeutic targets.
Table 1. List of neurological disorders and other clinical diseases that involves Netrin-1.
Author contributions
MC: Data curation, Investigation, Methodology, Writing – original draft, Writing – review & editing. QZ: Conceptualization, Data curation, Project administration, Writing – original draft. YC: Methodology, Resources, Validation, Writing – review & editing. SL: Methodology, Resources, Validation, Writing – review & editing. HZ: Supervision, Validation, Writing – review & editing. BB: Conceptualization, Data curation, Funding acquisition, Methodology, Supervision, Writing – review & editing.
Funding
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China (82172354, to BB), the Research Foundation of Jiangsu Provincial Commission of Health and Family Planning (M2021012 and LK2021028, to BB), the Nanjing Medical Science and Technology Development Foundation (ZKX22013, to BB), the fundings for Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University (2022-LCYJ-MS-02, to BB).
Acknowledgments
The authors thank all laboratory members for their helpful discussions.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Footnotes
References
Abdulfattah, S. Y., Baiomy, A. A. B., and Youssef, J. M. (2022). Is netrin-1 a reliable inflammatory marker for periodontitis? J. Adv. Periodontol. Implant Dent. 14, 1–6. doi: 10.34172/japid.2022.001
Ahn, E. H., Kang, S. S., Liu, X., Cao, X., Choi, S. Y., Musazzi, L., et al. (2021). BDNF and Netrin-1 repression by C/EBPbeta in the gut triggers Parkinson's disease pathologies, associated with constipation and motor dysfunctions. Prog. Neurobiol. 198:101905. doi: 10.1016/j.pneurobio.2020.101905
Ahn, E. H., Kang, S. S., Liu, X., Chen, G., Zhang, Z., Chandrasekharan, B., et al. (2020a). Initiation of Parkinson's disease from gut to brain by delta-secretase. Cell Res. 30, 70–87. doi: 10.1038/s41422-019-0241-9
Ahn, E. H., Kang, S. S., Qi, Q., Liu, X., and Ye, K. (2020b). Netrin 1 deficiency activates MST 1 via UNC 5B receptor, promoting dopaminergic apoptosis in Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 117, 24503–24513. doi: 10.1073/pnas.2004087117
Alzheimer's Disease Genetics ConsortiumWetzel-Smith, M. K., Hunkapiller, J., Bhangale, T. R., Srinivasan, K., Maloney, J. A., et al. (2014). A rare mutation in Unc5C predisposes to late-onset Alzheimer's disease and increases neuronal cell death. Nat. Med. 20, 1452–1457. doi: 10.1038/nm.3736
Aoki-Suzuki, M., Yamada, K., Meerabux, J., Iwayama-Shigeno, Y., Ohba, H., Iwamoto, K., et al. (2005). A family-based association study and gene expression analyses of netrin-G1 and -G2 genes in schizophrenia. Biol. Psychiatry 57, 382–393. doi: 10.1016/j.biopsych.2004.11.022
Arakawa, H. (2004). Netrin-1 and its receptors in tumorigenesis. Nat. Rev. Cancer 4, 978–987. doi: 10.1038/nrc1504
Ay, E., Marakoglu, K., Kizmaz, M., and Unlu, A. (2016). Evaluation of Netrin-1 levels and albuminuria in patients with diabetes. J. Clin. Lab. Anal. 30, 972–977. doi: 10.1002/jcla.21965
Bai, B., Wang, X., Li, Y., Chen, P. C., Yu, K., Dey, K. K., et al. (2020). Deep multilayer brain proteomics identifies molecular networks in Alzheimer's disease progression. Neuron 105, 975–991.e7. doi: 10.1016/j.neuron.2019.12.015
Berenji, M. G., Berenji, H. G., Pashapour, S., and Sadeghpour, S. (2022). Serum Netrin-1 and urinary KIM-1 levels as potential biomarkers for the diagnosis of early preeclampsia. J. Obstet. Gynaecol. 42, 636–640. doi: 10.1080/01443615.2021.1945010
Bin, J. M., Han, D., Lai Wing Sun, K., Croteau, L.-P., Dumontier, E., Cloutier, J.-F., et al. (2015). Complete loss of Netrin-1 results in embryonic lethality and severe axon guidance defects without increased neural cell death. Cell Rep. 12, 1099–1106. doi: 10.1016/j.celrep.2015.07.028
Bloom, G. S. (2014). Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 71, 505–508. doi: 10.1001/jamaneurol.2013.5847
Boneschansker, L., Nakayama, H., Eisenga, M., Wedel, J., Klagsbrun, M., Irimia, D., et al. (2016). Netrin-1 augments chemokinesis in CD4+ T cells in vitro and elicits a proinflammatory response in vivo. J. Immunol. 197, 1389–1398. doi: 10.4049/jimmunol.1502432
Borel, F., Marzocca, F., Delcros, J. G., Rama, N., Mehlen, P., and Ferrer, J. L. (2017). Molecular characterization of Netrin-1 and APP receptor binding: new leads to block the progression of senile plaques in Alzheimer's disease. Biochem. Biophys. Res. Commun. 488, 466–470. doi: 10.1016/j.bbrc.2017.05.056
Bouhidel, J. O., Wang, P., Li, Q., and Cai, H. (2014). Pharmacological postconditioning treatment of myocardial infarction with netrin-1. Front Biosci. 19:4227. doi: 10.2741/4227
Bouilly, J., Messina, A., Papadakis, G., Cassatella, D., Xu, C., Acierno, J. S., et al. (2018). DCC/NTN 1 complex mutations in patients with congenital hypogonadotropic hypogonadism impair GnRH neuron development. Hum. Mol. Genet. 27, 359–372. doi: 10.1093/hmg/ddx408
Boussouar, A., Tortereau, A., Manceau, A., Paradisi, A., Gadot, N., Vial, J., et al. (2020). Netrin-1 and its receptor dcc are causally implicated in melanoma progression. Cancer Res. 80, 747–756. doi: 10.1158/0008-5472.CAN-18-1590
Boyer, N. P., and Gupton, S. L. (2018). Revisiting netrin-1: one who guides (axons). Front. Cell. Neurosci. 12:221. doi: 10.3389/fncel.2018.00221
Braak, H., and Braak, E. (1996). Evolution of the neuropathology of Alzheimer's disease. Acta Neurol. Scand. Suppl. 165, 3–12.
Braak, H., De Vos, R. A., Bohl, J., and Del Tredici, K. (2006). Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci. Lett. 396, 67–72. doi: 10.1016/j.neulet.2005.11.012
Brignani, S., Raj, D. D. A., Schmidt, E. R. E., Dudukcu, O., Adolfs, Y., De Ruiter, A. A., et al. (2020). Remotely produced and axon-derived Netrin-1 instructs GABaergic neuron migration and dopaminergic substantia Nigra development. Neuron 107:e9. doi: 10.1016/j.neuron.2020.05.037
Broutier, L., Creveaux, M., Vial, J., Tortereau, A., Delcros, J. G., Chazot, G., et al. (2016). Targeting netrin-1/DCC interaction in diffuse large B-cell and mantle cell lymphomas. EMBO Mol. Med. 8, 96–104. doi: 10.15252/emmm.201505480
Bruikman, C. S., Vreeken, D., Hoogeveen, R. M., Bom, M. J., Danad, I., Pinto-Sietsma, S. J., et al. (2020a). Netrin-1 and the grade of atherosclerosis are inversely correlated in humans. Arterioscler. Thromb. Vasc. Biol. 40, 462–472. doi: 10.1161/ATVBAHA.119.313624
Bruikman, C. S., Vreeken, D., Zhang, H., Van Gils, M. J., Peter, J., Van Zonneveld, A. J., et al. (2020b). The identification and function of a Netrin-1 mutation in a pedigree with premature atherosclerosis. Atherosclerosis 301, 84–92. doi: 10.1016/j.atherosclerosis.2020.02.015
Burke, J. F., Kerber, K. A., Langa, K. M., Albin, R. L., and Kotagal, V. (2023). Lecanemab: looking before we leap. Neurology 101, 661–665. doi: 10.1212/WNL.0000000000207505
Cassier, P. A., Navaridas, R., Bellina, M., Rama, N., Ducarouge, B., Hernandez-Vargas, H., et al. (2023). Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer. Nature 620, 409–416. doi: 10.1038/s41586-023-06367-z
Cekmez, Y., Garip, S., Ulu, I., Gulsen, S., Haberal, E. T., Olgac, Y., et al. (2017). Maternal serum netrin-1 levels as a new biomarker of preeclampsia. J. Matern. Fetal Neonatal Med. 30, 1072–1074. doi: 10.1080/14767058.2016.1201471
Chen, Z., Cao, T., Zhong, X., Wu, Y., Fu, W., Fan, C., et al. (2022). Association between serum netrin-1 levels and early neurological deterioration after acute ischemic stroke. Front. Neurol. 13:953557. doi: 10.3389/fneur.2022.953557
Chen, Z., Cao, T., Zhong, X., Wu, Y., Fu, W., Fan, C., et al. (2020a). Decreased serum netrin-1 as a predictor for post-stroke depression in Chinese patients with acute ischemic stroke. J. Stroke Cerebrovasc. Dis. 29:105149. doi: 10.1016/j.jstrokecerebrovasdis.2020.105149
Chen, Z., Chen, Y., Zhou, J., Li, Y., Gong, C., and Wang, X. (2020b). Netrin-1 reduces lung ischemia-reperfusion injury by increasing the proportion of regulatory T cells. J. Int. Med. Res. 48:300060520926415. doi: 10.1177/0300060520926415
Chen, P. C., Han, X., Shaw, T. I., Fu, Y., Sun, H., Niu, M., et al. (2022). Alzheimer's disease-associated U1 snRNP splicing dysfunction causes neuronal hyperexcitability and cognitive impairment. Nat Aging 2, 923–940. doi: 10.1038/s43587-022-00290-0
Chen, G., Kang, S. S., Wang, Z., Ahn, E. H., Xia, Y., Liu, X., et al. (2021). Netrin-1 receptor UNC 5C cleavage by active delta-secretase enhances neurodegeneration, promoting Alzheimer's disease pathologies. Sci. Adv. 7, 1–15. doi: 10.1126/sciadv.abe4499
Chen, J. L., Yuan, D. H., Yang, S. J., Gu, C., Zhou, H. S., and Shao, G. F. (2019). Serum netrin-1 serves as a prognostic biomarker of aneurysmal subarachnoid hemorrhage. Clin. Chim. Acta 495, 294–300. doi: 10.1016/j.cca.2019.04.080
Cohen, O., Vald, L., Yamagata, M., Sanes, J. R., and Klar, A. (2017). Roles of DSCAM in axonal decussation and fasciculation of chick spinal interneurons. Int. J. Dev. Biol. 61, 235–244. doi: 10.1387/ijdb.160235ak
Corset, V., Nguyen-Ba-Charvet, K. T., Forcet, C., Moyse, E., Chedotal, A., and Mehlen, P. (2000). Netrin-1-mediated axon outgrowth and camp production requires interaction with adenosine A2b receptor. Nature 407, 747–750. doi: 10.1038/35037600
Couzin-Frankel, J. (2023). Side effects loom over Alzheimer's drugs. Science 381, 466–467. doi: 10.1126/science.adk0830
Cross-Disorder Group of the Psychiatric Genomics Consortium (2019). Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders. Cell 179:e11. doi: 10.1016/j.cell.2019.11.020
Cui, M. Z. (2015). Potential therapeutics for myocardial ischemia-reperfusion injury. Focus on "induction of cardioprotection by small netrin-1-derived peptides". Am. J. Physiol. Cell Physiol. 309, C97–C99. doi: 10.1152/ajpcell.00150.2015
De Breuck, S., Lardon, J., Rooman, I., and Bouwens, L. (2003). Netrin-1 expression in fetal and regenerating rat pancreas and its effect on the migration of human pancreatic duct and porcine islet precursor cells. Diabetologia 46, 926–933. doi: 10.1007/s00125-003-1125-5
Delloye-Bourgeois, C., Brambilla, E., Coissieux, M. M., Guenebeaud, C., Pedeux, R., Firlej, V., et al. (2009a). Interference with netrin-1 and tumor cell death in non-small cell lung cancer. J. Natl. Cancer Inst. 101, 237–247. doi: 10.1093/jnci/djn491
Delloye-Bourgeois, C., Fitamant, J., Paradisi, A., Cappellen, D., Douc-Rasy, S., Raquin, M. A., et al. (2009b). Netrin-1 acts as a survival factor for aggressive neuroblastoma. J. Exp. Med. 206, 833–847. doi: 10.1084/jem.20082299
Duyckaerts, C., Delatour, B., and Potier, M. C. (2009). Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 118, 5–36. doi: 10.1007/s00401-009-0532-1
Eikelenboom, P., and Stam, F. C. (1982). Immunoglobulins and complement factors in senile plaques. Acta Neuropathol. 57, 239–242. doi: 10.1007/BF00685397
Elkholy, R. A., Younis, R. L., Allam, A. A., Hagag, R. Y., and Abdel Ghafar, M. T. (2021). Diagnostic efficacy of serum and urinary netrin-1 in the early detection of diabetic nephropathy. J. Investig. Med. 69, 1189–1195. doi: 10.1136/jim-2021-001785
Emamzadeh, F. N., and Surguchov, A. (2018). Parkinson's disease: biomarkers, treatment, and risk factors. Front. Neurosci. 12:612. doi: 10.3389/fnins.2018.00612
Fiorelli, S., Cosentino, N., Porro, B., Fabbiocchi, F., Niccoli, G., Fracassi, F., et al. (2021). Netrin-1 in atherosclerosis: relationship between human macrophage intracellular levels and in vivo plaque morphology. Biomedicines 9, 1–11. doi: 10.3390/biomedicines9020168
Fitamant, J., Guenebeaud, C., Coissieux, M. M., Guix, C., Treilleux, I., Scoazec, J. Y., et al. (2008). Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer. Proc. Natl. Acad. Sci. U. S. A. 105, 4850–4855. doi: 10.1073/pnas.0709810105
Flores, C. (2011). Role of netrin-1 in the organization and function of the mesocorticolimbic dopamine system. J. Psychiatry Neurosci. 36, 296–310. doi: 10.1503/jpn.100171
Forsyth, C. B., Shannon, K. M., Kordower, J. H., Voigt, R. M., Shaikh, M., Jaglin, J. A., et al. (2011). Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One 6:e28032. doi: 10.1371/journal.pone.0028032
Franz, E. A., Chiaroni-Clarke, R., Woodrow, S., Glendining, K. A., Jasoni, C. L., Robertson, S. P., et al. (2015). Congenital mirror movements: phenotypes associated with DCC and RAD 51 mutations. J. Neurol. Sci. 351, 140–145. doi: 10.1016/j.jns.2015.03.006
Gao, S., Zhang, X., Qin, Y., Xu, S., Zhang, J., Wang, Z., et al. (2016). Dual actions of Netrin-1 on islet insulin secretion and immune modulation. Clin. Sci. (Lond.) 130, 1901–1911. doi: 10.1042/CS20160133
Glasgow, S. D., Ruthazer, E. S., and Kennedy, T. E. (2021). Guiding synaptic plasticity: novel roles for netrin-1 in synaptic plasticity and memory formation in the adult brain. J. Physiol. 599, 493–505. doi: 10.1113/JP278704
Glendining, K. A., Markie, D., Gardner, R. J., Franz, E. A., Robertson, S. P., and Jasoni, C. L. (2017). A novel role for the DNA repair gene RAD 51 in Netrin-1 signalling. Sci. Rep. 7:39823. doi: 10.1038/srep39823
Grandin, M., Meier, M., Delcros, J. G., Nikodemus, D., Reuten, R., Patel, T. R., et al. (2016). Structural decoding of the Netrin-1/UNC 5 interaction and its therapeutical implications in cancers. Cancer Cell 29, 173–185. doi: 10.1016/j.ccell.2016.01.001
Greenfield, J. P., Tsai, J., Gouras, G. K., Hai, B., Thinakaran, G., Checler, F., et al. (1999). Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer beta-amyloid peptides. Proc. Natl. Acad. Sci. U. S. A. 96, 742–747. doi: 10.1073/pnas.96.2.742
Gunpinar, S., Meraci, B., and Dundar, N. (2020). Netrin-1 and its receptor Unc5b as markers of periodontal disease. J. Periodontal Res. 55, 267–276. doi: 10.1111/jre.12712
Guo, D., Qiao, Y., Li, Z., Zhu, Z., Peng, H., Zhang, Q., et al. (2020). Decreased serum netrin-1 is associated with ischemic stroke: a case-control study. Nutr. Metab. Cardiovasc. Dis. 30, 2328–2334. doi: 10.1016/j.numecd.2020.07.034
Guo, D., Zhu, Z., Zhong, C., Peng, H., Wang, A., Xu, T., et al. (2019). Increased serum Netrin-1 is associated with improved prognosis of ischemic stroke. Stroke 50, 845–852. doi: 10.1161/STROKEAHA.118.024631
Gyengesi, E., and Munch, G. (2020). In search of an anti-inflammatory drug for Alzheimer disease. Nat. Rev. Neurol. 16, 131–132. doi: 10.1038/s41582-019-0307-9
Haass, C., and Selkoe, D. J. (2007). Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8, 101–112. doi: 10.1038/nrm2101
Heppner, F. L., Ransohoff, R. M., and Becher, B. (2015). Immune attack: the role of inflammation in Alzheimer disease. Nat. Rev. Neurosci. 16, 358–372. doi: 10.1038/nrn3880
Hoops, D., and Flores, C. (2017). Making dopamine connections in adolescence. Trends Neurosci. 40, 709–719. doi: 10.1016/j.tins.2017.09.004
Hu, H., Kahrizi, K., Musante, L., Fattahi, Z., Herwig, R., Hosseini, M., et al. (2019). Genetics of intellectual disability in consanguineous families. Mol. Psychiatry 24, 1027–1039. doi: 10.1038/s41380-017-0012-2
Hua, Y., Han, W., Zhou, L., Gao, J., Zhao, J., Song, N., et al. (2023). An imbalance of netrin-1 and DCC during nigral degeneration in experimental models and patients with Parkinson's disease. CNS Neurosci. Ther. 29, 1817–1829. doi: 10.1111/cns.14141
Iossifov, I., O'roak, B. J., Sanders, S. J., Ronemus, M., Krumm, N., Levy, D., et al. (2014). The contribution of de novo coding mutations to autism spectrum disorder. Nature 515, 216–221. doi: 10.1038/nature13908
Jasmin, M., Ahn, E. H., Voutilainen, M. H., Fombonne, J., Guix, C., Viljakainen, T., et al. (2021). Netrin-1 and its receptor dcc modulate survival and death of dopamine neurons and Parkinson's disease features. EMBO J. 40:e105537. doi: 10.15252/embj.2020105537
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., et al. (2012). A mutation in app protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96–99. doi: 10.1038/nature11283
Ju, T., Sun, L., Fan, Y., Wang, T., Liu, Y., Liu, D., et al. (2021). Decreased Netrin-1 in mild cognitive impairment and Alzheimer's disease patients. Front. Aging Neurosci. 13:762649. doi: 10.3389/fnagi.2021.762649
Kanekiyo, T., Cirrito, J. R., Liu, C. C., Shinohara, M., Li, J., Schuler, D. R., et al. (2013). Neuronal clearance of amyloid-beta by endocytic receptor LRP1. J. Neurosci. 33, 19276–19283. doi: 10.1523/JNEUROSCI.3487-13.2013
Kang, E. J., Jang, S. M., Lee, Y. J., Jeong, Y. J., Kim, Y. J., Kang, S. S., et al. (2023). The couple of netrin-1/alpha-Synuclein regulates the survival of dopaminergic neurons via alpha-Synuclein disaggregation. BMB Rep. 56, 126–131. doi: 10.5483/BMBRep.2023-0004
Kaya, S., Turhan, U., Dag, I., and Polat, I. (2023). Association of maternal serum Netrin-1 and Netrin-4 levels with placenta accreta spectrum. Eur. Rev. Med. Pharmacol. Sci. 27, 4594–4600. doi: 10.26355/eurrev_202305_32466
Kefeli, U., Ucuncu Kefeli, A., Cabuk, D., Isik, U., Sonkaya, A., Acikgoz, O., et al. (2017). Netrin-1 in cancer: potential biomarker and therapeutic target? Tumour Biol. 39:1010428317698388. doi: 10.1177/1010428317698388
Kefeli, U., Yildirim, M. E., Aydin, D., Madenci, O. C., Yasar, N., Sener, N., et al. (2012). Netrin-1 concentrations in patients with advanced gastric cancer and its relation with treatment. Biomarkers 17, 663–667. doi: 10.3109/1354750X.2012.709882
Kelly, L. P., Carvey, P. M., Keshavarzian, A., Shannon, K. M., Shaikh, M., Bakay, R. A., et al. (2014). Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease. Mov. Disord. 29, 999–1009. doi: 10.1002/mds.25736
Kim, M. S., Pinto, S. M., Getnet, D., Nirujogi, R. S., Manda, S. S., Chaerkady, R., et al. (2014). A draft map of the human proteome. Nature 509, 575–581. doi: 10.1038/nature13302
Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., and Lamb, B. T. (2018). Inflammation as a central mechanism in Alzheimer's disease. Alzheimers Dement 4, 575–590. doi: 10.1016/j.trci.2018.06.014
Kokulu, K., Mutlu, H., and Sert, E. T. (2020). Serum netrin-1 levels at presentation and delayed neurological sequelae in unintentional carbon monoxide poisoning. Clin. Toxicol. (Phila.) 58, 1313–1319. doi: 10.1080/15563650.2020.1743302
Lemons, M. L., Abanto, M. L., Dambrouskas, N., Clements, C. C., Deloughery, Z., Garozzo, J., et al. (2013). Integrins and camp mediate netrin-induced growth cone collapse. Brain Res. 1537, 46–58. doi: 10.1016/j.brainres.2013.08.045
Leng, F., and Edison, P. (2021). Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat. Rev. Neurol. 17, 157–172. doi: 10.1038/s41582-020-00435-y
Lengrand, J., Pastushenko, I., Vanuytven, S., Song, Y., Venet, D., Sarate, R. M., et al. (2023). Pharmacological targeting of netrin-1 inhibits EMT in cancer. Nature 620, 402–408. doi: 10.1038/s41586-023-06372-2
Leocadio, P., Menta, P., Dias, M., Fraga, J., Goulart, A., Santos, I., et al. (2020). High serum Netrin-1 and Il-1beta in elderly females with ACS: worse prognosis in 2-years follow-up. Arq. Bras. Cardiol. 114, 507–514. doi: 10.36660/abc.20190035
Lewis, M. A., Nolan, L. S., Cadge, B. A., Matthews, L. J., Schulte, B. A., Dubno, J. R., et al. (2018). Whole exome sequencing in adult-onset hearing loss reveals a high load of predicted pathogenic variants in known deafness-associated genes and identifies new candidate genes. BMC Med. Genet. 11:77. doi: 10.1186/s12920-018-0395-1
Li, Y., Chai, J. L., Shi, X., Feng, Y., Li, J. J., Zhou, L. N., et al. (2023). Galphai1/3 mediate Netrin-1-CD146-activated signaling and angiogenesis. Theranostics 13, 2319–2336. doi: 10.7150/thno.80749
Li, J., Duarte, T., Kocabas, A., Works, M., Mcconnell, S. K., and Hynes, M. A. (2014). Evidence for topographic guidance of dopaminergic axons by differential Netrin-1 expression in the striatum. Mol. Cell. Neurosci. 61, 85–96. doi: 10.1016/j.mcn.2014.05.003
Li, B., Shen, K., Zhang, J., Jiang, Y., Yang, T., Sun, X., et al. (2020). Serum netrin-1 as a biomarker for colorectal cancer detection. Cancer Biomark. 28, 391–396. doi: 10.3233/CBM-190340
Liu, J., Du, J., Cheng, X., Zhang, X., Li, Y., Fu, X., et al. (2019). Effect of Netrin-1 anti-inflammatory factor on acute lung injury in Sepsis rats. Med. Sci. Monit. 25, 7928–7935. doi: 10.12659/MSM.917279
Liu, C., Ke, X., Wang, Y., Feng, X., Li, Q., Zhang, Y., et al. (2016). The level of netrin-1 is decreased in newly diagnosed type 2 diabetes mellitus patients. BMC Endocr. Disord. 16:33. doi: 10.1186/s12902-016-0112-z
Liu, G., Li, W., Wang, L., Kar, A., Guan, K. L., Rao, Y., et al. (2009). DSCAM functions as a netrin receptor in commissural axon pathfinding. Proc. Natl. Acad. Sci. U. S. A. 106, 2951–2956. doi: 10.1073/pnas.0811083106
Llambi, F., Causeret, F., Bloch-Gallego, E., and Mehlen, P. (2001). Netrin-1 acts as a survival factor via its receptors UNC5H and DCC. EMBO J. 20, 2715–2722. doi: 10.1093/emboj/20.11.2715
Lo, P. S., Rymar, V. V., Kennedy, T. E., and Sadikot, A. F. (2022). The netrin-1 receptor dcc promotes the survival of a subpopulation of midbrain dopaminergic neurons: relevance for ageing and Parkinson's disease. J. Neurochem. 161, 254–265. doi: 10.1111/jnc.15579
Lou, X. H., Cai, Y. Y., Yang, X. Q., Zheng, H. J., Yu, Y. J., Wang, C. H., et al. (2020). Serum netrin-1 concentrations are associated with clinical outcome in acute intracerebral hemorrhage. Clin. Chim. Acta 508, 154–160. doi: 10.1016/j.cca.2020.05.032
Lourenco, F. C., Galvan, V., Fombonne, J., Corset, V., Llambi, F., Muller, U., et al. (2009). Netrin-1 interacts with amyloid precursor protein and regulates amyloid-beta production. Cell Death Differ. 16, 655–663. doi: 10.1038/cdd.2008.191
Lu, X., Le Noble, F., Yuan, L., Jiang, Q., De Lafarge, B., Sugiyama, D., et al. (2004). The netrin receptor Unc5B mediates guidance events controlling morphogenesis of the vascular system. Nature 432, 179–186. doi: 10.1038/nature03080
Ly, A., Nikolaev, A., Suresh, G., Zheng, Y., Tessier-Lavigne, M., and Stein, E. (2008). DSCAM is a netrin receptor that collaborates with DCC in mediating turning responses to netrin-1. Cell 133, 1241–1254. doi: 10.1016/j.cell.2008.05.030
Marshall, K. E., Vadukul, D. M., Staras, K., and Serpell, L. C. (2020). Misfolded amyloid-beta-42 impairs the endosomal-lysosomal pathway. Cell. Mol. Life Sci. 77, 5031–5043. doi: 10.1007/s00018-020-03464-4
Martin, L., Latypova, X., Wilson, C. M., Magnaudeix, A., Perrin, M. L., Yardin, C., et al. (2013). Tau protein kinases: involvement in Alzheimer's disease. Ageing Res. Rev. 12, 289–309. doi: 10.1016/j.arr.2012.06.003
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., and Cummings, J. L. (2015). Alzheimer's disease. Nat. Rev. Dis. Primers 1:15056. doi: 10.1038/nrdp.2015.56
Matsukawa, H., Akiyoshi-Nishimura, S., Zhang, Q., Lujan, R., Yamaguchi, K., Goto, H., et al. (2014). Netrin-G/NGL complexes encode functional synaptic diversification. J. Neurosci. 34, 15779–15792. doi: 10.1523/JNEUROSCI.1141-14.2014
Mehlen, P., Delloye-Bourgeois, C., and Chedotal, A. (2011). Novel roles for slits and netrins: axon guidance cues as anticancer targets? Nat. Rev. Cancer 11, 188–197. doi: 10.1038/nrc3005
Meneret, A., Depienne, C., Riant, F., Trouillard, O., Bouteiller, D., Cincotta, M., et al. (2014). Congenital mirror movements: mutational analysis of RAD51 and DCC in 26 cases. Neurology 82, 1999–2002. doi: 10.1212/WNL.0000000000000477
Meneret, A., Franz, E. A., Trouillard, O., Oliver, T. C., Zagar, Y., Robertson, S. P., et al. (2017). Mutations in the netrin-1 gene cause congenital mirror movements. J. Clin. Invest. 127, 3923–3936. doi: 10.1172/JCI95442
Meng, Y., Sun, S., Cao, S., and Shi, B. (2022). Netrin-1: a serum marker predicting cognitive impairment after spinal cord injury. Dis. Markers 2022:1033197. doi: 10.1155/2022/1033197
Moore, S. W., and Kennedy, T. E. (2006). Protein kinase a regulates the sensitivity of spinal commissural axon turning to netrin-1 but does not switch between chemoattraction and chemorepulsion. J. Neurosci. 26, 2419–2423. doi: 10.1523/JNEUROSCI.5419-05.2006
Moore, S. W., Lai Wing Sun, K., Xie, F., Barker, P. A., Conti, M., and Kennedy, T. E. (2008). Soluble adenylyl cyclase is not required for axon guidance to netrin-1. J. Neurosci. 28, 3920–3924. doi: 10.1523/JNEUROSCI.0547-08.2008
Moore, S. W., Tessier-Lavigne, M., and Kennedy, T. E. (2007). Netrins and their receptors. Adv. Exp. Med. Biol. 621, 17–31. doi: 10.1007/978-0-387-76715-4_2
Mrak, R. E. (2012). Microglia in Alzheimer brain: a neuropathological perspective. Int. J. Alzheimers Dis. 2012:165021. doi: 10.1155/2012/165021
Mrak, R. E., and Griffin, W. S. (2005). Glia and their cytokines in progression of neurodegeneration. Neurobiol. Aging 26, 349–354. doi: 10.1016/j.neurobiolaging.2004.05.010
Mulero, P., Cordova, C., Hernandez, M., Martin, R., Gutierrez, B., Munoz, J. C., et al. (2017). Netrin-1 and multiple sclerosis: a new biomarker for neuroinflammation? Eur. J. Neurol. 24, 1108–1115. doi: 10.1111/ene.13340
Munoz, J. C., Martin, R., Alonso, C., Gutierrez, B., and Nieto, M. L. (2017). Relation between serum levels of chemotaxis-related factors and the presence of coronary artery calcification as expression of subclinical atherosclerosis. Clin. Biochem. 50, 1048–1055. doi: 10.1016/j.clinbiochem.2017.08.012
Nedeva, I., Gateva, A., Assyov, Y., Karamfilova, V., Velikova, T., and Kamenov, Z. (2022). Relationship between circulating netrin-1 levels, obesity, prediabetes and newly diagnosed type 2 diabetes. Arch. Physiol. Biochem. 128, 1533–1538. doi: 10.1080/13813455.2020.1780453
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., et al. (2012). Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J. Neuropathol. Exp. Neurol. 71, 362–381. doi: 10.1097/NEN.0b013e31825018f7
Nguyen, A., and Cai, H. (2006). Netrin-1 induces angiogenesis via a DCC-dependent ERK1/2-eNOS feed-forward mechanism. Proc. Natl. Acad. Sci. U. S. A. 103, 6530–6535. doi: 10.1073/pnas.0511011103
Ohm, T. G., Muller, H., Braak, H., and Bohl, J. (1995). Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer's disease-related neurofibrillary changes. Neuroscience 64, 209–217. doi: 10.1016/0306-4522(95)90397-P
Osborne, P. B., Halliday, G. M., Cooper, H. M., and Keast, J. R. (2005). Localization of immunoreactivity for deleted in colorectal cancer (dcc), the receptor for the guidance factor netrin-1, in ventral tier dopamine projection pathways in adult rodents. Neuroscience 131, 671–681. doi: 10.1016/j.neuroscience.2004.11.043
Palmesino, E., Haddick, P. C., Tessier-Lavigne, M., and Kania, A. (2012). Genetic analysis of DSCAM'S role as a Netrin-1 receptor in vertebrates. J. Neurosci. 32, 411–416. doi: 10.1523/JNEUROSCI.3563-11.2012
Paradisi, A., Maisse, C., Bernet, A., Coissieux, M. M., Maccarrone, M., Scoazec, J. Y., et al. (2008). NF-kappaB regulates netrin-1 expression and affects the conditional tumor suppressive activity of the netrin-1 receptors. Gastroenterology 135, 1248–1257. doi: 10.1053/j.gastro.2008.06.080
Paradisi, A., Maisse, C., Coissieux, M. M., Gadot, N., Lepinasse, F., Delloye-Bourgeois, C., et al. (2009). Netrin-1 up-regulation in inflammatory bowel diseases is required for colorectal cancer progression. Proc. Natl. Acad. Sci. U. S. A. 106, 17146–17151. doi: 10.1073/pnas.0901767106
Park, K. W., Crouse, D., Lee, M., Karnik, S. K., Sorensen, L. K., Murphy, K. J., et al. (2004). The axonal attractant Netrin-1 is an angiogenic factor. Proc. Natl. Acad. Sci. U. S. A. 101, 16210–16215. doi: 10.1073/pnas.0405984101
Petit, A., Sellers, D. L., Liebl, D. J., Tessier-Lavigne, M., Kennedy, T. E., and Horner, P. J. (2007). Adult spinal cord progenitor cells are repelled by netrin-1 in the embryonic and injured adult spinal cord. Proc. Natl. Acad. Sci. U. S. A. 104, 17837–17842. doi: 10.1073/pnas.0703240104
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., et al. (2017). Parkinson disease. Nat Rev Dis Primers 3:17013. doi: 10.1038/nrdp.2017.13
Rajasekharan, S., and Kennedy, T. E. (2009). The netrin protein family. Genome Biol. 10:239. doi: 10.1186/gb-2009-10-9-239
Rama, N., Goldschneider, D., Corset, V., Lambert, J., Pays, L., and Mehlen, P. (2012). Amyloid precursor protein regulates netrin-1-mediated commissural axon outgrowth. J. Biol. Chem. 287, 30014–30023. doi: 10.1074/jbc.M111.324780
Ramesh, G., Berg, A., and Jayakumar, C. (2011). Plasma netrin-1 is a diagnostic biomarker of human cancers. Biomarkers 16, 172–180. doi: 10.3109/1354750X.2010.541564
Ramesh, G., Krawczeski, C. D., Woo, J. G., Wang, Y., and Devarajan, P. (2010). Urinary netrin-1 is an early predictive biomarker of acute kidney injury after cardiac surgery. Clin. J. Am. Soc. Nephrol. 5, 395–401. doi: 10.2215/CJN.05140709
Ramkhelawon, B., Hennessy, E. J., Menager, M., Ray, T. D., Sheedy, F. J., Hutchison, S., et al. (2014). Netrin-1 promotes adipose tissue macrophage retention and insulin resistance in obesity. Nat. Med. 20, 377–384. doi: 10.1038/nm.3467
Ranganathan, P. V., Jayakumar, C., and Ramesh, G. (2013). Netrin-1-treated macrophages protect the kidney against ischemia-reperfusion injury and suppress inflammation by inducing M2 polarization. Am. J. Physiol. Renal Physiol. 304, F948–F957. doi: 10.1152/ajprenal.00580.2012
Reeves, W. B., Kwon, O., and Ramesh, G. (2008). Netrin-1 and kidney injury. Ii. Netrin-1 is an early biomarker of acute kidney injury. Am. J. Physiol. Renal Physiol. 294, F731–F738. doi: 10.1152/ajprenal.00507.2007
Schlegel, M., Kohler, D., Korner, A., Granja, T., Straub, A., Giera, M., et al. (2016). The neuroimmune guidance cue netrin-1 controls resolution programs and promotes liver regeneration. Hepatology 63, 1689–1705. doi: 10.1002/hep.28347
Sert, Z. S. (2022). The role of serum netrin-1 level in the detection of early-onset preeclampsia. Eur. J. Obstet. Gynecol. Reprod. Biol. 270, 164–168. doi: 10.1016/j.ejogrb.2022.01.010
Shabani, M., Haghani, M., Tazangi, P. E., Bayat, M., Shid Moosavi, S. M., and Ranjbar, H. (2017). Netrin-1 improves the amyloid-beta-mediated suppression of memory and synaptic plasticity. Brain Res. Bull. 131, 107–116. doi: 10.1016/j.brainresbull.2017.03.015
Sollvander, S., Nikitidou, E., Brolin, R., Soderberg, L., Sehlin, D., Lannfelt, L., et al. (2016). Accumulation of amyloid-beta by astrocytes result in enlarged endosomes and microvesicle-induced apoptosis of neurons. Mol. Neurodegener. 11:38. doi: 10.1186/s13024-016-0098-z
Spilman, P. R., Corset, V., Gorostiza, O., Poksay, K. S., Galvan, V., Zhang, J., et al. (2016). Netrin-1 interrupts amyloid-beta amplification, increases sAbetaPPalpha in vitro and in vivo, and improves cognition in a mouse model of Alzheimer's disease. J. Alzheimers Dis. 52, 223–242. doi: 10.3233/JAD-151046
Stanco, A., Szekeres, C., Patel, N., Rao, S., Campbell, K., Kreidberg, J. A., et al. (2009). Netrin-1-alpha3beta1 integrin interactions regulate the migration of interneurons through the cortical marginal zone. Proc. Natl. Acad. Sci. U. S. A. 106, 7595–7600. doi: 10.1073/pnas.0811343106
Stenson, P. D., Mort, M., Ball, E. V., Chapman, M., Evans, K., Azevedo, L., et al. (2020). The human gene mutation database (HGMD((R))): optimizing its use in a clinical diagnostic or research setting. Hum. Genet. 139, 1197–1207. doi: 10.1007/s00439-020-02199-3
Sun, L. W., Correia, J. P., and Kennedy, T. E. (2011). Netrins: versatile extracellular cues with diverse functions. Development 138, 2153–2169. doi: 10.1242/dev.044529
Sun, L., Ju, T., Wang, T., Zhang, L., Ding, F., Zhang, Y., et al. (2019). Decreased Netrin-1 and correlated Th17/Tregs balance disorder in Abeta (1-42) induced Alzheimer's disease model rats. Front. Aging Neurosci. 11:124. doi: 10.3389/fnagi.2019.00124
Sung, P. J., Rama, N., Imbach, J., Fiore, S., Ducarouge, B., Neves, D., et al. (2019). Cancer-associated fibroblasts produce Netrin-1 to control Cancer cell plasticity. Cancer Res. 79, 3651–3661. doi: 10.1158/0008-5472.CAN-18-2952
Tahami Monfared, A. A., Byrnes, M. J., White, L. A., and Zhang, Q. (2022). Alzheimer's disease: epidemiology and clinical progression. Neurol Ther 11, 553–569. doi: 10.1007/s40120-022-00338-8
Tak, E., Ridyard, D., Badulak, A., Giebler, A., Shabeka, U., Werner, T., et al. (2013). Protective role for netrin-1 during diabetic nephropathy. J. Mol. Med. (Berl) 91, 1071–1080. doi: 10.1007/s00109-013-1041-1
Tan, H., Wu, Z., Wang, H., Bai, B., Li, Y., Wang, X., et al. (2015). Refined phosphopeptide enrichment by phosphate additive and the analysis of human brain phosphoproteome. Proteomics 15, 500–507. doi: 10.1002/pmic.201400171
Tang, X., Jang, S. W., Okada, M., Chan, C. B., Feng, Y., Liu, Y., et al. (2008). Netrin-1 mediates neuronal survival through pike-L interaction with the dependence receptor Unc5B. Nat. Cell Biol. 10, 698–706. doi: 10.1038/ncb1732
Tenner, A. J. (2020). Complement-mediated events in Alzheimer's disease: mechanisms and potential therapeutic targets. J. Immunol. 204, 306–315. doi: 10.4049/jimmunol.1901068
Torres-Berrio, A., Hernandez, G., Nestler, E. J., and Flores, C. (2020). The Netrin-1/dcc guidance Cue pathway as a molecular target in depression: translational evidence. Biol. Psychiatry 88, 611–624. doi: 10.1016/j.biopsych.2020.04.025
Tu, T., Zhang, C., Yan, H., Luo, Y., Kong, R., Wen, P., et al. (2015). CD146 acts as a novel receptor for netrin-1 in promoting angiogenesis and vascular development. Cell Res. 25, 275–287. doi: 10.1038/cr.2015.15
Van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., et al. (2023). Lecanemab in early Alzheimer's disease. N. Engl. J. Med. 388, 9–21. doi: 10.1056/NEJMoa2212948
van Gils, J. M., Derby, M. C., Fernandes, L. R., Ramkhelawon, B., Ray, T. D., Rayner, K. J., et al. (2012). The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaques. Nat. Immunol. 13, 136–143. doi: 10.1038/ni.2205
Van Gils, J. M., Ramkhelawon, B., Fernandes, L., Stewart, M. C., Guo, L., Seibert, T., et al. (2013). Endothelial expression of guidance cues in vessel wall homeostasis dysregulation under proatherosclerotic conditions. Arterioscler. Thromb. Vasc. Biol. 33, 911–919. doi: 10.1161/ATVBAHA.112.301155
Vosberg, D. E., Leyton, M., and Flores, C. (2020). The Netrin-1/dcc guidance system: dopamine pathway maturation and psychiatric disorders emerging in adolescence. Mol. Psychiatry 25, 297–307. doi: 10.1038/s41380-019-0561-7
Wang, Z. H., Gong, K., Liu, X., Zhang, Z., Sun, X., Wei, Z. Z., et al. (2018). C/EBPbeta regulates delta-secretase expression and mediates pathogenesis in mouse models of Alzheimer's disease. Nat. Commun. 9:1784. doi: 10.1038/s41467-018-04120-z
Xia, X., Hu, Z., Wang, S., and Yin, K. (2022). Netrin-1: An emerging player in inflammatory diseases. Cytokine Growth Factor Rev. 64, 46–56. doi: 10.1016/j.cytogfr.2022.01.003
Xie, Y., Guo, Z., Chen, F., Xiao, C., Xu, J., and Bo, D. (2021). Serum netrin-1 as a potential biomarker for functional outcome of traumatic brain injury. Clin. Chim. Acta 518, 22–27. doi: 10.1016/j.cca.2021.03.008
Yang, Y. H., Szabat, M., Bragagnini, C., Kott, K., Helgason, C. D., Hoffman, B. G., et al. (2011). Paracrine signalling loops in adult human and mouse pancreatic islets: netrins modulate beta cell apoptosis signalling via dependence receptors. Diabetologia 54, 828–842. doi: 10.1007/s00125-010-2012-5
Yildirim, M. E., Kefeli, U., Aydin, D., Sener, N., and Gumus, M. (2016). The value of plasma netrin-1 in non-small cell lung cancer patients as diagnostic and prognostic biomarker. Tumour Biol. 37, 11903–11907. doi: 10.1007/s13277-016-5025-y
Yim, J., Kim, G., Lee, B. W., Kang, E. S., Cha, B. S., Kim, J. H., et al. (2018). Relationship between circulating Netrin-1 concentration, impaired fasting glucose, and newly diagnosed type 2 diabetes. Front. Endocrinol. 9:691. doi: 10.3389/fendo.2018.00691
Yu, M., Sporns, O., and Saykin, A. J. (2021). The human connectome in Alzheimer disease - relationship to biomarkers and genetics. Nat. Rev. Neurol. 17, 545–563. doi: 10.1038/s41582-021-00529-1
Yung, A. R., Nishitani, A. M., and Goodrich, L. V. (2015). Phenotypic analysis of mice completely lacking netrin 1. Development 142, 3686–3691. doi: 10.1242/dev.128942
Zamani, E., Parviz, M., Roghani, M., Hosseini, M., Mohseni-Moghaddam, P., and Nikbakhtzadeh, M. (2020). Netrin-1 protects the Sh-Sy5Y cells against amyloid beta neurotoxicity through Nf-kappaB/Nrf2 dependent mechanism. Mol. Biol. Rep. 47, 9271–9277. doi: 10.1007/s11033-020-05996-1
Zamani, E., Parviz, M., Roghani, M., and Mohseni-Moghaddam, P. (2019). Key mechanisms underlying netrin-1 prevention of impaired spatial and object memory in Abeta(1-42) Ca1-injected rats. Clin. Exp. Pharmacol. Physiol. 46, 86–93. doi: 10.1111/1440-1681.13020
Zang, Y., Guo, D., Chen, L., Yang, P., Zhu, Z., Bu, X., et al. (2021). Association between serum netrin-1 and prognosis of ischemic stroke: the role of lipid component levels. Nutr. Metab. Cardiovasc. Dis. 31, 852–859. doi: 10.1016/j.numecd.2020.11.004
Zhang, J., and Cai, H. (2010). Netrin-1 prevents ischemia/reperfusion-induced myocardial infarction via a DCC/ERK1/2/eNOS s1177/NO/DCC feed-forward mechanism. J. Mol. Cell. Cardiol. 48, 1060–1070. doi: 10.1016/j.yjmcc.2009.11.020
Zhang, X., Qin, J., Wang, X., Guo, X., Liu, J., Wang, X., et al. (2018). Netrin-1 improves adipose-derived stem cell proliferation, migration, and treatment effect in type 2 diabetic mice with sciatic denervation. Stem Cell Res Ther 9:285. doi: 10.1186/s13287-018-1020-0
Keywords: Netrin-1, neurodegeneration, Alzheimer’s disease, Parkinson’s disease, psychiatric disorder, mirror movement
Citation: Cai M, Zheng Q, Chen Y, Liu S, Zhu H and Bai B (2024) Insights from the neural guidance factor Netrin-1 into neurodegeneration and other diseases. Front. Mol. Neurosci. 17:1379726. doi: 10.3389/fnmol.2024.1379726
Edited by:
Andrei Surguchov, University of Kansas Medical Center, United StatesReviewed by:
Irina G. Sourgoutcheva, University of Kansas Medical Center, United StatesPartha Chattopadhyay, College of Medicine & Sagore Dutta Hospital, India
Copyright © 2024 Cai, Zheng, Chen, Liu, Zhu and Bai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Bing Bai, YmluZy5iYWlAbmp1LmVkdS5jbg==
†These authors have contributed equally to this work and share first authorship